Traditional Chinese medicine composition for preventing epidemic virus as well as preparation method, application and product thereof

Abstract

The invention belongs to the field of traditional Chinese medicine compositions, and particularly relates to a traditional Chinese medicine composition for preventing epidemic viruses as well as a preparation method, application and a product thereof. The traditional Chinese medicine composition is prepared from the following components: 10 to 15 parts of roasted herba ephedrae, 10 to 20 parts of radix puerariae, 10 to 15 parts of radix bupleuri, 10 to 20 parts of gypsum, 10 to 20 parts of poria cocos, 10 to 20 parts of honeysuckle flower, 10 to 15 parts of fructus forsythiae, 10 to 15 parts of herba artemisiae annuae, 10 to 20 parts of herba cirsii japonici, 10 to 15 parts of fructus arctii and 10 to 15 parts of radix platycodonis. The preparation method of the traditional Chinese medicine composition comprises the following steps: weighing roasted herba ephedrae, radix puerariae, radix bupleuri, gypsum, poria cocos, honeysuckle, fructus forsythiae, artemisia apiacea, circium japonicum, fructus arctii and platycodon grandiflorum, adding water, decocting, filtering, concentrating and cooling to obtain the traditional Chinese medicine composition. The traditional Chinese medicine composition prepared from the components by the preparation method has good anti-inflammatory, analgesic, heat-clearing and detoxifying effects.

Description

Technical Field

[0001] The present invention belongs to the field of Chinese medicine compositions, and in particular relates to a Chinese medicine composition for preventing epidemic viruses, a preparation method thereof, an application thereof, and a product thereof. Background Art

[0002] Upper respiratory tract infection usually refers to inflammation including the nasal cavity, pharynx or larynx. 70%-80% are caused by viruses, mainly parainfluenza virus, adenovirus, rhinovirus, coronavirus, etc. Western medicine treatment of upper respiratory tract infection mainly focuses on symptomatic treatment, often using antipyretic analgesics, antitussive drugs, decongestants and expectorants. There is currently no specific antiviral drug specifically for upper respiratory tract infection. Vaccination is a relatively effective preventive measure, but because there are many types of viruses that cause upper respiratory tract infections, they are easy to mutate and immunity is not long-lasting, so it is still very difficult to widely use vaccines for prevention.

[0003] Traditional Chinese medicine classifies this disease as "exogenous fever", which is caused by the six evils or warm and hot epidemic toxic qi, leading to disharmony between the Ying and Wei, imbalance of yin and yang in the internal organs, pathological fever, and aversion to cold, flushed face, irritability, and rapid pulse as the main clinical manifestations. Traditional Chinese medicine has a long history and is widely used in antipyretic, analgesic and anti-inflammatory. Commonly used Chinese medicines, such as Bupleurum, Ephedra, Asarum, etc., have significant effects in antipyretic, analgesic and anti-inflammatory. In addition, some Chinese medicine prescriptions are also widely used in the treatment of antipyretic, analgesic and anti-inflammatory. The classic prescription Guizhi Decoction, composed of cinnamon twig, peony, ginger, jujube, etc., has the effects of dispelling cold, warming and unblocking the meridians, and harmonizing the Ying and Wei. It is often used to treat symptoms such as colds, headaches, and fever. Huanglian Jiedu Decoction recorded in "Emergency Prescriptions for the Elbow" is composed of four herbs: Scutellaria baicalensis, Coptis chinensis, Phellodendron chinense, and Gardenia jasminoides. It has the effects of clearing away heat and dampness, purging fire and detoxifying, and is mainly used to treat all symptoms of triple-burner fire and internal heat and toxicity. At present, commercially available Chinese herbal compound preparations, such as Qingre Jiedu Granules, Isatis Root, and Huanglian Jiedu Tablets, all have good antipyretic and anti-inflammatory effects and are often used to treat upper respiratory tract infections, acute tonsillitis and other diseases.

[0004] For example, Chinese patent CN 104547688A discloses the use of a Chinese medicine composition in preparing a drug for treating hemorrhoids. The invention is mainly prepared from the following raw materials: 11-23 parts of andrographis paniculata, 5-12 parts of psoralea corylifolia, 10-20 parts of costusroot, 13-27 parts of wolfberry, 8-19 parts of pinellia tuber, 11-24 parts of phytolacca, 13-26 parts of agrimony, 14-28 parts of cyperus rotundus, 7-18 parts of red peony root, 12-27 parts of codonopsis pilosula, 12-29 parts of cassia twig, 10-18 parts of angelica dahurica, 6-18 parts of bupleurum, 5-12 parts of sambucus, 10-22 parts of mint, 5-16 parts of tribulus terrestris, 7-18 parts of burdock fruit, 10-21 parts of oldenlandia diffusa, 5-14 parts of achyranthes bidentata, 4-11 parts of cirsium japonicum, 10-20 parts of dodder seed, 6-12 parts of cattle bone powder, 15-32 parts of tuckahoe and 20-30 parts of liquorice. Pharmacological experiments and clinical trials have confirmed its significant analgesic and anti-inflammatory activities. It has significant efficacy, is safe and reliable, and has broad prospects for clinical application. However, it has too many components, resulting in high cost.

[0005] For example, Chinese patent CN 116077594A discloses a Chinese medicine for treating respiratory viral infection, which includes the following raw materials in weight proportion: 45-55 parts of ephedra, 80-90 parts of Pseudostellariae Radix, 63-73 parts of Bupleurum, 63-73 parts of Scutellariae Radix, 63-73 parts of Patchouli, 80-90 parts of Honeysuckle, 80-90 parts of Forsythiae, 30-40 parts of Platycodon, 80-90 parts of Burdock Fructus, 130-150 parts of Phragmites australis, 63-73 parts of Isatis Radix, 63-73 parts of Scrophulariae Radix, 25-35 parts of Apricot Kernel, and 63-73 parts of Radix Phellodendri. The invention has the effects of dispelling cold and relieving heat and toxins. Mainly used to treat epidemic diseases, influenza, common colds with wind-cold binding the surface and heat-toxicity internalization clinically, and have no sweat, bad sweat, fever, muscle and joint soreness, pain, headache, sore throat, dry throat and itchy throat, dry cough and less sputum, etc. Chinese medicine of the present invention can be used clinically for the treatment of febrile diseases and respiratory diseases in all seasons. But in the preparation process, flavoring agents and preservatives are also added, although the mouthfeel can be improved and the shelf life can be extended, safety issues may also be brought, such as may cause adverse reactions, allergic reactions, affect drug efficacy and stability, and potential health risks to children and special physique populations. In addition, long-term intake of certain additives may also cause cumulative poisoning and negative effects on the immune system.

[0006] In summary, there is an urgent need to develop a safe Chinese medicine composition with few ingredients, suitable for preventing various viruses and having good heat-clearing, detoxifying, anti-inflammatory and analgesic effects, and a preparation method thereof. Summary of the invention

[0007] Based on the deficiencies of the prior art, the present invention aims to provide a safe Chinese medicine composition with few ingredients, suitable for preventing various viruses and having good heat-clearing and detoxifying, anti-inflammatory and analgesic effects and a preparation method thereof. The Chinese medicine composition comprises the following components: roasted ephedra, kudzu root, bupleurum, gypsum, tuckahoe, honeysuckle, forsythia, artemisia annua, cirsium, burdock fruit and platycodon.

[0008] In order to achieve the above object, the present invention adopts the following technical solutions:

[0009] In a first aspect, the present invention provides a traditional Chinese medicine composition for preventing epidemic viruses, which comprises the following components by weight: 10-15 parts of roasted ephedra, 10-20 parts of kudzu root, 10-15 parts of bupleurum, 10-20 parts of gypsum, 10-20 parts of poria, 10-20 parts of honeysuckle, 10-15 parts of forsythia, 10-15 parts of artemisia annua, 10-20 parts of cirsium japonicum, 10-15 parts of burdock fruit and 10-15 parts of platycodon.

[0010] Preferably, the Chinese medicine composition comprises the following components by weight: 8-12 parts of roasted ephedra, 12-18 parts of kudzu root, 8-10 parts of bupleurum, 13-15 parts of gypsum, 12-15 parts of poria, 10-15 parts of honeysuckle, 8-10 parts of forsythia, 10-15 parts of artemisia annua, 12-18 parts of cirsium japonicum, 10-15 parts of burdock fruit, and 8-12 parts of platycodon.

[0011] Preferably, the weight ratio of honeysuckle, bupleurum and forsythia is 1.5-2:1.2-1.5:1.2-1.5.

[0012] More preferably, the weight ratio of honeysuckle, bupleurum and forsythia is 1.5:1:1.

[0013] As a most preferred embodiment, the Chinese medicine composition includes the following components by weight: 10 parts of roasted ephedra, 15 parts of kudzu root, 10 parts of bupleurum, 15 parts of gypsum, 15 parts of poria, 15 parts of honeysuckle, 10 parts of forsythia, 12 parts of artemisia annua, 15 parts of cirsium japonicum, 12 parts of burdock fruit and 10 parts of platycodon.

[0014] The drug mechanism selected by each component of the present invention is:

[0015] Ephedra is the herbaceous stem of the plant Ephedra sinica, Ephedra equisetum or Ephedra intermedia. It is warm in nature, pungent in taste and slightly bitter. Roasted Ephedra is made by stir-frying raw Ephedra with honey. It has the effects of sweating and dispelling cold, clearing the lungs and relieving asthma, and absorbing water and reducing swelling. Roasted Ephedra can be used to treat colds caused by wind and cold, and is particularly good for exogenous cold syndrome.

[0016] Pueraria root is the dried root of the leguminous plant Pueraria lobata. It tastes sweet, spicy and cool. It has the effects of relieving muscle and fever, clearing rashes, promoting body fluid and quenching thirst, raising yang and stopping diarrhea, promoting blood circulation and activating collaterals, and detoxifying alcohol. Flavonoid compounds such as puerarin are the main active ingredients of Pueraria root, which have multiple effects such as suppressing cough, lowering body temperature, anti-inflammatory and swelling, anti-oxidation, and protecting cardiovascular system.

[0017] Bupleurum is the dried root of the Umbelliferae plant Bupleurum or Bupleurum angustifolia. It tastes pungent and bitter, and is slightly cold in nature. It has the effects of reconciling the exterior and interior, soothing the liver and relieving depression, raising yang and lifting depression, and reducing fever and stopping malaria. Bupleurum has a wide range of central nervous system inhibitory effects such as sedation, stability, analgesia, antipyretic, and antitussive. Its active ingredient, saikosaponin, has anti-inflammatory effects, and its anti-inflammatory effect is related to promoting the function of the adrenal cortex system.

[0018] Gypsum has the effects of clearing away heat and purging fire, relieving restlessness and quenching thirst, and can be used to treat various symptoms such as heat syndrome of febrile diseases, lung heat, cough and asthma. Studies have shown that calcium ions can inhibit the release and activity of inflammatory mediators, reduce tissue inflammatory response, and thus play an antipyretic, analgesic and anti-inflammatory role.

[0019] Poria cocos is the dried sclerotium of the fungus. It tastes sweet and light, is neutral in nature, and has the effects of promoting diuresis and removing dampness, strengthening the spleen, and calming the mind. Poria cocos does not directly have an antipyretic effect. However, because it has the effects of promoting diuresis and removing swelling, removing dampness and strengthening the spleen, it can help regulate the water balance in the body, thereby relieving the fever symptoms caused by excessive dampness and heat in the body to a certain extent. The active ingredients such as Poria cocos polysaccharides and Pachycolic acid have anti-inflammatory effects, can reduce inflammatory reactions, and help treat inflammatory diseases such as infection and pain caused by inflammation, and some diseases related to inflammation.

[0020] Honeysuckle is the dried buds or flowers of honeysuckle and the same genus of the Caprifoliaceae family. It is a good medicine for clearing away heat and detoxifying. Honeysuckle has a significant effect of clearing away heat and detoxifying. It is often used to treat various febrile diseases, such as fever, rash, spots, heat toxic sores, sore throat, etc.; it can evacuate wind-heat and has a certain effect on relieving fever, headache, dry throat and other symptoms caused by wind-heat exogenous infection.

[0021] Forsythia suspensa tastes bitter and is slightly cold in nature. It has the effects of clearing away heat and detoxifying, reducing swelling and dispersing nodules. It is often used to treat symptoms such as exogenous wind-heat and the initial stage of febrile diseases. It can be used together with honeysuckle, burdock seeds, etc. to enhance the effect of clearing heat and detoxifying. The active ingredients such as forsythia phenol and forsythia glycoside can stimulate the production of neurotransmitters in the body, thereby playing an analgesic and antipyretic role. This is very effective in relieving fever and pain caused by colds, flu, etc. The aloin and other ingredients in Forsythia suspensa have anti-inflammatory effects and can relieve swelling and pain caused by inflammation. This has a good effect on treating symptoms such as skin infections, sores, carbuncles, etc.

[0022] Artemisia annua is the dried or fresh aerial part of the Asteraceae plant Artemisia annua. It is bitter, pungent and cold in nature and has the effects of clearing away heat from the body, removing bone steaming, relieving summer heat, stopping malaria and relieving jaundice. Modern research also shows that the active ingredients in Artemisia annua include artemisinin and flavonoid compounds, which have multiple pharmacological effects such as antibacterial, anti-inflammatory, antiviral and antimalarial.

[0023] Cirsium japonicum is the dried aerial part of the cirsium of the Asteraceae family. It is sweet, bitter and cool in nature and has the effects of cooling blood and stopping bleeding, removing blood stasis and reducing swelling. Cirsium japonicum has the effect of clearing heat and cooling blood, which can help remove heat toxins from the body, thereby helping to relieve fever symptoms. Secondly, Cirsium japonicum can also disperse blood stasis, detoxify and eliminate carbuncle, and has a certain effect on relieving symptoms such as heat toxin sores, carbuncle, redness, swelling, heat and pain, which also indirectly has the effect of relieving fever and relieving pain. It can also promote blood circulation, increase oxygen supply to tissues, accelerate the repair and regeneration of damaged tissues, thereby relieving swelling, pain and inflammation.

[0024] Burdock seeds are the mature fruits of the burdock plant of the Asteraceae family. They are pungent, bitter, and cold in nature. They have the effects of dispersing wind-heat, clearing the lungs and clearing rashes, relieving sore throat and dispersing knots, and detoxifying and reducing swelling. They belong to the dispersing wind-heat medicine among the antipyretic drugs. Burdock seeds are cool in nature and pungent in taste. They can dispel wind and heat, clear away heat and detoxify, clear the lungs and eliminate phlegm. They can be used for wind-heat colds, and can also relieve symptoms such as throat suppuration, sputum, and hemoptysis. The effective ingredients such as isoimperatorin and magnolia alkaloids have the effect of inhibiting the activation and secretion of inflammatory cells, thereby showing anti-inflammatory activity. This makes burdock seeds have a certain improvement effect on the symptoms of local redness, swelling, heat, and pain caused by diseases such as acute gastroenteritis and bronchitis. The volatile oil and saponin in burdock seeds have certain antibacterial activity, which can inhibit the growth and reproduction of various bacteria and fungi, thereby playing an antibacterial role. This helps prevent and treat diseases such as skin infections and respiratory infections.

[0025] Platycodon grandiflorum is bitter and pungent in taste and has a neutral nature. It has many functions such as clearing away heat and detoxifying, calming the mind and calming the spirit, removing phlegm and relieving cough, promoting diuresis and reducing swelling, and relieving the exterior and promoting lung function. Platycodon grandiflorum can dispel cold and promote sweat discharge, thereby improving cold symptoms such as cough and fever. Platycodon grandiflorum has the function of clearing heat and detoxifying, which means that it can help lower body temperature and relieve the discomfort caused by heat toxins. Therefore, Platycodon grandiflorum is often used clinically to treat heat toxin diseases, such as carbuncle, sore throat, etc. It can effectively remove heat toxins from the body, thereby playing a role in relieving fever. Platycodon grandiflorum also has anti-inflammatory effects. Studies have shown that platycodon saponins can enhance the phagocytic ability of macrophages and the bactericidal ability of leukocytes, thereby helping the body resist inflammation. In addition, Platycodon grandiflorum can inhibit the release of inflammatory mediators, reduce inflammatory reactions, and relieve pain and swelling caused by inflammation.

[0026] The whole prescription combines a small amount of pungent and warm ingredients with pungent and cool ingredients, which is beneficial for expelling pathogens without violating the meaning of pungent and cool ingredients. At the same time, it disperses wind-heat and clears heat and detoxifies, which not only disperses wind-heat externally, but also detoxifies and eliminates filth. This prescription uses both warming and clearing, focusing on pungent and cool to clear heat; it treats both the exterior and the interior, focusing on dredging and dispersing, and plays the role of clearing heat and detoxifying, promoting lung function and relieving cough, and relieving throat and promoting body fluid.

[0027] In a second aspect, the present invention provides a method for preparing the above-mentioned traditional Chinese medicine composition for preventing epidemic viruses, which specifically comprises the following steps: weighing roasted ephedra, kudzu root, bupleurum, gypsum, poria, honeysuckle, forsythia, artemisia annua, cirsium japonicum, burdock fruit and platycodon, soaking in water, decocting, filtering, concentrating and cooling to obtain the traditional Chinese medicine composition.

[0028] Preferably, the water-adding and decocting process adopts a condensation reflux device; the condensation reflux time is 0.5-1.5h; and the number of condensation reflux is 1-3 times.

[0029] More preferably, the condensation reflux time is 1.5 hours; and the condensation reflux is repeated twice.

[0030] Preferably, the mass ratio of the water added to the liquid is 1:5-25.

[0031] More preferably, the mass ratio of the water added to the liquid is 1:10.

[0032] Preferably, the soaking time is 0h-1h; more preferably, the soaking time is 45min.

[0033] Preferably, the filtration is performed while hot using gauze.

[0034] Preferably, the concentration standard is to concentrate to less than 500 mL.

[0035] Preferably, the cooling standard is cooling to room temperature.

[0036] Preferably, the fixed volume is 500 mL.

[0037] In a third aspect, the present invention also provides the use of the above-mentioned traditional Chinese medicine composition for preventing epidemic viruses in the preparation of anti-inflammatory, analgesic, heat-clearing and detoxifying products.

[0038] In a fourth aspect, the present invention also provides a product of the above-mentioned Chinese medicine composition for preventing epidemic viruses.

[0039] The dosage form of the product is granules, tablets, capsules or oral liquid.

[0040] Compared with the prior art, the present invention has the following beneficial effects:

[0041] (1) The present invention improves the synergistic effect between the components by controlling the specific types and ratios of the active ingredients of the drug, thereby improving the effect of preventing various symptoms caused by epidemic viruses.

[0042] (2) The present invention is simple and feasible to operate, and the product quality is controllable. DETAILED DESCRIPTION

[0043] The present invention is further described in detail below with reference to specific embodiments.

[0044] Example 1 A Chinese medicine composition for preventing epidemic viruses and its preparation method

[0045] The Chinese medicine composition comprises the following components by weight:

[0046] 10 parts of roasted ephedra, 15 parts of kudzu root, 10 parts of bupleurum, 15 parts of gypsum, 15 parts of tuckahoe, 15 parts of honeysuckle, 10 parts of forsythia, 12 parts of artemisia annua, 15 parts of cirsium japonicum, 12 parts of burdock fruit and 10 parts of platycodon.

[0047] The preparation method comprises the following steps:

[0048] Weigh roasted ephedra, kudzu root, bupleurum, gypsum, tuckahoe, honeysuckle, forsythia, artemisia annua, cirsium japonicum, burdock fruit and platycodon, add water according to the material-liquid mass ratio of 1:10, soak for 45 minutes, decoct, condense and reflux for 1.5 hours, condense and reflux extraction twice, filter while hot with gauze, concentrate in a water bath to less than 500 mL, cool to room temperature, and adjust the volume of a volumetric flask to 500 mL to obtain the traditional Chinese medicine composition.

[0049] Example 2 A Chinese medicine composition for preventing epidemic viruses and its preparation method

[0050] The Chinese medicine composition comprises the following components by weight:

[0051] 15 parts of roasted ephedra, 20 parts of kudzu root, 15 parts of bupleurum, 20 parts of gypsum, 20 parts of tuckahoe, 20 parts of honeysuckle, 15 parts of forsythia, 15 parts of artemisia annua, 20 parts of cirsium japonicum, 15 parts of burdock fruit and 15 parts of platycodon.

[0052] The preparation method comprises the following steps:

[0053] Weigh roasted ephedra, kudzu root, bupleurum, gypsum, tuckahoe, honeysuckle, forsythia, artemisia annua, cirsium japonicum, burdock fruit and platycodon, add water at a material-liquid mass ratio of 1:25, soak for 0 min, condense and reflux for 0.5 hour, condense and reflux extraction once, filter with gauze while hot, concentrate in a water bath to less than 500 mL, cool to room temperature, and adjust the volume of a volumetric flask to 500 mL to obtain the traditional Chinese medicine composition.

[0054] Example 3 A Chinese medicine composition for preventing epidemic viruses and its preparation method

[0055] The Chinese medicine composition comprises the following components by weight:

[0056] 8 parts of roasted ephedra, 20 parts of kudzu root, 10 parts of bupleurum, 10 parts of gypsum, 10 parts of tuckahoe, 10 parts of honeysuckle, 10 parts of forsythia, 10 parts of artemisia annua, 10 parts of cirsium japonicum, 10 parts of burdock fruit and 10 parts of platycodon.

[0057] The preparation method comprises the following steps:

[0058] Weigh roasted ephedra, kudzu root, bupleurum, gypsum, tuckahoe, honeysuckle, forsythia, artemisia annua, cirsium japonicum, burdock fruit and platycodon, add water at a material-liquid mass ratio of 1:5, soak for 60 minutes, condense and reflux for 1.5 hours, condense and reflux extraction for 3 times, filter while hot with gauze, concentrate in a water bath to less than 500 mL, cool to room temperature, and adjust the volume of a volumetric flask to 500 mL to obtain the traditional Chinese medicine composition.

[0059] Example 4 A Chinese medicine composition for preventing epidemic viruses and its preparation method

[0060] The Chinese medicine composition comprises the following components by weight: 12 parts of roasted ephedra, 18 parts of kudzu root, 12 parts of bupleurum, 18 parts of gypsum, 18 parts of tuckahoe, 15 parts of honeysuckle, 12 parts of forsythia, 15 parts of artemisia annua, 18 parts of cirsium japonicum, 15 parts of burdock fruit and 12 parts of platycodon.

[0061] The preparation method is the same as that in Example 1.

[0062] Example 5 A Chinese medicine composition for preventing epidemic viruses and its preparation method

[0063] The Chinese medicine composition comprises the following components by weight: 8 parts of roasted ephedra, 16 parts of kudzu root, 15 parts of bupleurum, 16 parts of gypsum, 16 parts of tuckahoe, 20 parts of honeysuckle, 15 parts of forsythia, 12 parts of artemisia annua, 16 parts of cirsium japonicum, 12 parts of burdock fruit and 8 parts of platycodon.

[0064] The preparation method is the same as that in Example 1.

[0065] Comparative Example 1 A Chinese medicine composition for preventing epidemic viruses and its preparation method

[0066] The Chinese medicine composition comprises the following components by weight:

[0067] The difference from Example 1 is that the weight of each component is different, but the total weight is the same, specifically: 20 parts of roasted ephedra, 5 parts of kudzu root, 10 parts of bupleurum, 15 parts of gypsum, 15 parts of tuckahoe, 15 parts of honeysuckle, 5 parts of forsythia, 12 parts of artemisia annua, 15 parts of cirsium japonicum, 17 parts of burdock fruit and 10 parts of platycodon.

[0068] The preparation method is the same as that in Example 1.

[0069] Comparative Example 2 A Chinese medicine composition for preventing epidemic viruses and its preparation method

[0070] The Chinese medicine composition comprises the following components by weight:

[0071] The difference from Example 1 is only that the ingredients are different, 15 parts of Radix Isatidis are used instead of 15 parts of Flos Lonicerae, and the other ingredients and qualities are the same as those in Example 1.

[0072] The preparation method comprises the following steps:

[0073] Weigh roasted ephedra, kudzu root, bupleurum, gypsum, poria, isatis root, forsythia, artemisia annua, cirsium japonicum, burdock fruit and platycodon, add water according to the material-liquid mass ratio of 1:10, soak for 45 minutes, decoct, condense and reflux for 1.5 hours, condense and reflux extraction twice, filter while hot with gauze, concentrate in a water bath to less than 500 mL, cool to room temperature, and adjust the volume of a volumetric flask to 500 mL to obtain the traditional Chinese medicine composition.

[0074] Effect test:

[0075] Basic pharmacodynamics study of drug combination for antipyretic, analgesic and anti-inflammatory effects:

[0076] Dose setting: According to the latest conversion method of drug dose between humans and animals and the results of preliminary experiments, the Chinese medicine composition uses the equivalent dose of rats and mice of the normal adult daily dose as the high dose, and the medium and low doses are designed in a 2-fold decrease. The high, medium and low doses of the Chinese medicine composition are 14.40, 7.20 and 3.60 g / kg respectively, and the aspirin dose is 20 mg / kg. The dosage volume for rats is 10 mL / kg, and the dosage volume for mice is 20 mL / kg.

[0077] Abbreviations of non-Chinese words: CON = blank control group, MOD = model group, ASA = aspirin group, QL = low-dose group, QM = medium-dose group, QH = high-dose group, LPS = lipopolysaccharide

[0078] Experimental Example 1

[0079] Effects of drug combination on dry yeast-induced fever model in rats

[0080] 1.1 Experimental Materials

[0081] 1.1.1 Experimental animals

[0082] Adult SD rats, male, SPF grade, weighing 200 g, were purchased from Zhuhai Baishitong Biotechnology Co., Ltd., with experimental animal production license number SYXK (Guangdong) 2020-0125. After 7 days of adaptive feeding, the experimental period began.

[0083] 1.1.2 Experimental drugs

[0084] Blank control: normal saline

[0085] Positive control: enteric-coated aspirin tablets, Bayer, batch number: BJ67758.

[0086] 1.1.3 Experimental reagents

[0087] The experimental reagents are shown in Table 1.

[0088] Table 1

[0089] Product Name factory batch number Highly Active Dry Yeast Angel Yeast Co., Ltd. SC13153312404747 Sodium Carboxymethyl Cellulose SIGMA-ALORICH SLBR1692V glycerin BioFroxx GmbH EZ7890B462

[0090] 1.1.4 Experimental instruments

[0091] The experimental instruments are shown in Table 2.

[0092] Table 2

[0093] instrument factory MC-347 Electronic Thermometer Omron (Dalian) Co., Ltd.

[0094] 1.2 Experimental methods

[0095] 1.2.1 Establishment of dry yeast-induced fever model

[0096] SPF-grade 200g young male SD rats were fed adaptively for 3 days, and the rectal temperature of the rats was measured once in the morning and afternoon every day. Before each rectal temperature measurement, the electronic thermometer probe was coated with glycerin, the rats were allowed to empty their feces, and then inserted 2cm into the rectum of the young rats (a red marker was used to mark the 2cm position of the electronic thermometer to ensure that the insertion depth was consistent each time), and the body temperature value was recorded after the reading stabilized (each rat was measured 3 times), and the rats were adapted to the environment and temperature measurement stimulation for 3 consecutive days.

[0097] According to the body temperature results of rats for three consecutive days, rats with a body temperature of 36.5-38.0°C and a change of no more than 0.5°C were selected for the experiment. The qualified rats were randomly divided into CON, MOD, ASA, Example 1Q-L, Example 1Q-M, Example 1Q-H, Example 2Q-M, Example 3Q-M, Example 4Q-M, Example 5Q-M, Comparative Example 1Q-M, Comparative Example 2Q-M, 10 rats in each group. After intragastric administration on the 3rd day, except for the normal control group, 20% dry yeast suspension (10mL / kg) was subcutaneously injected into the back of rats in each group to establish a fever model, and the normal control group was injected with an equal volume of physiological saline. The body temperature of rats in each group was measured every 1h after modeling, for a total of 10 times. The modeling was considered successful when the body temperature of rats increased by >0.8°C 6h after modeling.

[0098] 1.2.2 Antipyretic treatment

[0099] After the model was successfully established, the rats in each group were given drug treatment when their body temperature was the highest. The body temperature of the rats in each group was measured every 1 hour after drug administration, for a total of 6 times.

[0100] 1.3 Experimental Results

[0101] 1.3.1 Establishment of fever in rats

[0102] The body temperature of rats in each group during each period of model establishment is shown in Table 3.

[0103] Table 3

[0104]

[0105]

[0106] Note: Compared with CON group, ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05

[0107] Compared with the CON group, the rats in the MOD group showed a significant cooling trend 2 hours after modeling; the body temperature began to rise at the 5th hour, and the temperature difference was extremely significant at the 6th hour (P<0.0001), which met the characteristics of fever change of dry yeast: there was a rapid and obvious temperature drop stage, which returned to normal at 4 hours, and then rose rapidly to reach a peak at 6-9 hours, which was relatively stable and lasted for a long time. The modeling was successful when the body temperature of the rats increased by >0.8℃ 6 hours after modeling, as shown in Table 3.

[0108] 1.3.2 Antipyretic treatment

[0109] The body temperatures of rats in each group after antipyretic treatment are shown in Table 4.

[0110] Table 4

[0111]

[0112]

[0113] Note: Compared with the Control group, ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05;

[0114] Compared with the Model group, ####P<0.0001, ###P<0.001, ##P<0.01, #P<0.05

[0115] Compared with the MOD group, the body temperature of rats in each group decreased after antipyretic treatment. Compared with the MOD group, the body temperature of QH rats decreased significantly at 4h after treatment (P<0.0001), as shown in Table 4. The body temperature of the comparative group did not decrease as significantly as that of the example group.

[0116] Experimental Example 2

[0117] Effects of drug combination on LPS-induced fever model in mice

[0118] 2.1 Experimental Materials

[0119] 2.1.1 Experimental animals

[0120] SPF female KM mice, weighing 18-20 g, 120 mice, were provided by Zhuhai Baishitong Biotechnology Co., Ltd., with the experimental animal production license number SYXK (Guangdong) 2022-0125. The experimental period began after 7 days of adaptive feeding.

[0121] 2.1.2 Experimental reagents

[0122] The experimental reagents are shown in Table 5.

[0123] Table 5

[0124] Product Name factory batch number LPS O111:B4 SIGMA L2630

[0125] 2.1.3 Experimental instruments

[0126] The experimental instruments are shown in Table 6.

[0127] Table 6

[0128] instrument factory MP150 Multichannel Physiological Recorder BIOPAC

[0129] 2.2 Experimental methods

[0130] 2.2.1 Establishment of LPS-induced fever model

[0131] SPF-grade 18-20g male KM mice were fed adaptively for 3 days, and the rectal temperature of the mice was measured once a day. Before each rectal temperature measurement, the temperature probe equipped with MP150 was coated with glycerin, the mice were allowed to empty their feces, and then inserted into the rectum of the young mice 1.5cm (marked with a red marker at 1.5cm of the temperature probe to ensure the same insertion depth each time), and the temperature value was recorded after the MP150 instrument reading stabilized, and the temperature was allowed to adapt to the environment and temperature measurement stimulation for 3 consecutive days.

[0132] According to the body temperature results of three consecutive days of temperature measurement, the mice were randomly divided into CON, MOD, ASA, Example 1Q-L, Example 1Q-M, Example 1Q-H, Example 2Q-M, Example 3Q-M, Example 4Q-M, Example 5Q-M, Comparative Example 1Q-M, and Comparative Example 2Q-M, with 10 mice in each group. CON and MOD were gavaged with normal saline at 9:00-11:00 every day, and the other drug groups were gavaged with corresponding drugs for 3 consecutive days.

[0133] LPS was injected intraperitoneally (3 μL / g) at a dose of 150 μg / kg, and an equal amount of saline was injected intraperitoneally for CON. The experimental environment temperature was 30°C, and mice had free access to water. After the model was successfully established, the body temperature of mice in each group was measured every 30 minutes, for a total of 5 times. The model was considered successful if the body temperature of the mice increased by >0.5°C 30 minutes after the model was established.

[0134] 2.2.2 Antipyretic treatment

[0135] After successful modeling, the mice in each group were given drug treatment when their body temperature was the highest. The body temperature of the mice in each group was measured every 30 minutes after drug administration for a total of 5 times.

[0136] 2.3 Experimental Results

[0137] 2.3.1 Establishment of mouse fever model and antipyretic treatment

[0138] The body temperatures of mice in each group at each time period are shown in Table 7.

[0139] Table 7

[0140]

[0141]

[0142] Note: Compared with the Control group, ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05;

[0143] Compared with the Model group, ####P<0.0001, ###P<0.001, ##P<0.01, #P<0.05

[0144] Compared with CON, the body temperature of MOD and other drug-treated groups increased significantly 30 minutes after intraperitoneal injection of LPS (P<0.0001). The modeling was successful when the body temperature of the modeled mice increased by 0.5°C. After the modeling was successful, each group was treated with drug therapy 30 minutes after modeling. Compared with MOD, the body temperature of ASA and QH mice decreased 30 minutes after drug administration, and the temperature of ASA mice decreased significantly (P<0.0001), as shown in Table 7.

[0145] Experimental Example 3

[0146] Hot plate pain test in mice

[0147] 3.1 Experimental Materials

[0148] 3.1.1 Experimental animals

[0149] SPF female KM mice, weighing 18-22 g, 50 mice, were provided by Zhuhai Baishitong Biotechnology Co., Ltd., with the experimental animal production license number SYXK (Guangdong) 2022-0125. The experimental period began after 7 days of adaptive feeding.

[0150] 3.1.2 Experimental reagents

[0151] The experimental reagents are shown in Table 8.

[0152] Table 8

[0153] Product Name factory batch number acetic acid Tianjin Damao Chemical Reagent Factory -

[0154] 3.1.3 Experimental instruments

[0155] The experimental instruments are shown in Table 9.

[0156] Table 9

[0157]

[0158] 3.2 Experimental methods

[0159] 3.2.1 Mouse hot plate experiment

[0160] After 3 days of adaptive feeding, SPF female KM mice (18-25g) were randomly divided into CON, MOD, ASA, Example 1Q-L, Example 1Q-M, Example 1Q-H, Example 2Q-M, Example 3Q-M, Example 4Q-M, Example 5Q-M, Comparative Example 1Q-M, Comparative Example 2Q-M according to body weight balance, with 10 mice in each group. The drugs were administered at a fixed time every day for 3 consecutive days. The mice were fasted but not watered 10 hours before the last administration; the hot plate test was performed 1 hour before and 1 hour after the last administration.

[0161] 3.3 Observation indicators

[0162] One hour before and after the third administration, licking the hind paw was used as a pain response index, and the time of pain response (pain threshold) was recorded. If the pain threshold exceeded 60 seconds, it was counted as 60 seconds, and the pain threshold increase rate of each group of mice was calculated.

[0163] The calculation formula is:

[0164] Pain threshold increase percentage (%) = (pain threshold 1 hour after drug administration - pain threshold 1 hour before drug administration) / pain threshold 1 hour before drug administration * 100

[0165] 3.4 Experimental Results

[0166] 3.4.1 Mouse hot plate experiment

[0167] The pain thresholds of mice in each group are shown in Table 10.

[0168] Table 10

[0169]

[0170] Note: Compared with the Control group, ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05

[0171] Compared with CON, 1 h before administration, there was no significant difference in the pain thresholds of mice in MOD, ASA, Example 1Q-L, Example 1Q-M, Example 1Q-H, Example 2Q-M, Example 3Q-M, Example 4Q-M, Example 5Q-M, Comparative Example 1Q-M, and Comparative Example 2Q-M groups; 1 h after administration, the pain threshold of ASA mice was extremely significantly increased (P<0.001), the pain threshold of QH mice was equivalent to that of the ASA group, and the pain thresholds of the examples and comparative examples were both increased (P<0.05), as shown in Table 10.

[0172] Experimental Example 4

[0173] Acetic acid-induced writhing experiment in mice

[0174] 4.1 Experimental Materials

[0175] 4.1.1 Experimental animals

[0176] SPF female KM mice, weighing 18-22 g, 50 mice, were provided by Zhuhai Baishitong Biotechnology Co., Ltd., with the experimental animal production license number SYXK (Guangdong) 2022-0125. The experimental period began after 7 days of adaptive feeding.

[0177] 4.1.2 Experimental reagents

[0178] The experimental reagents are shown in Table 11.

[0179] Table 11

[0180] Product Name factory batch number acetic acid Tianjin Damao Chemical Reagent Factory -

[0181] 4.1.3 Experimental instruments

[0182] The experimental instruments are shown in Table 12.

[0183] Table 12

[0184] instrument factory counter Self-provided by the Laboratory of Traditional Chinese Medicine Research Institute (Integrated Chinese and Western Medicine for Metabolic Diseases of Guangdong Province)

[0185] 4.2 Experimental methods

[0186] 4.2.1 Mouse writhing test

[0187] After 3 days of adaptive feeding, SPF female KM mice (18-22g) were randomly divided into CON, MOD, ASA, Example 1Q-L, Example 1Q-M, Example 1Q-H, Example 2Q-M, Example 3Q-M, Example 4Q-M, Example 5Q-M, Comparative Example 1Q-M, Comparative Example 2Q-M according to body weight balance, with 10 mice in each group. The drugs were administered at a fixed time every day for 3 consecutive days. The mice were fasted but not watered 10 hours before the last administration; 1 hour after the last administration, the acetic acid-induced mouse writhing experiment was performed.

[0188] 4.3 Observation indicators

[0189] One hour after the last administration, 0.2 mL of 0.6% acetic acid was injected intraperitoneally, and the number of first writhing reactions (abdomen concavity, hind limb extension, buttocks elevation, crawling) of mice in each group was observed within 10 minutes after the injection of acetic acid.

[0190] 4.4 Experimental Results

[0191] 4.4.1 Mouse writhing test

[0192] The number of writhing times of mice in each group is shown in Table 13.

[0193] Table 13

[0194] Group Twist times / times CON 0 MOD 84.6±6.57**** ASA 38.8±3.23****#### Example 1Q-L 42.6±2.20****#### Example 1Q-M 39.1±2.18****#### Example 1Q-H 31.0±3.32****#### Example 2Q-M 42.0±7.56*# Example 3Q-M 43.0±8.23* Example 4Q-M 40.2±6.98**# Example 5Q-M 39.5±6.82***# Comparative Example 1Q-M 65.2±4.09 Comparative Example 2Q-M 78.2±6.32

[0195] Note: Compared with the Control group, ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05;

[0196] Compared with the Model group, ####P<0.0001, ###P<0.001, ##P<0.01, #P<0.05

[0197] Compared with CON, the number of twisting in the other groups was significantly different (P<0.0001). Compared with MOD, the analgesic effect of each drug group was significantly improved (P<0.0001), and the analgesic effect of QM and ASA was similar, see Table 13.

[0198] Experimental Example 5

[0199] Xylene-induced ear swelling experiment in mice

[0200] 5.1 Experimental Materials

[0201] 5.1.1 Experimental animals

[0202] SPF female KM mice, weighing 18-22 g, 50 mice, were provided by Zhuhai Baishitong Biotechnology Co., Ltd., with the experimental animal production license number SYXK (Guangdong) 2022-0125. The experimental period began after 7 days of adaptive feeding.

[0203] 5.1.2 Experimental reagents

[0204] The experimental reagents are shown in Table 14.

[0205] Table 14

[0206] Product Name factory batch number acetic acid Tianjin Damao Chemical Reagent Factory -

[0207] 5.1.3 Experimental instruments

[0208] The experimental instruments are shown in Table 15.

[0209] Table 15

[0210]

[0211] 5.2 Experimental methods

[0212] 5.2.1 Mouse ear swelling experiment

[0213] After 3 days of adaptive feeding, SPF female KM mice (18-22g) were randomly divided into CON, MOD, ASA, Example 1Q-L, Example 1Q-M, Example 1Q-H, Example 2Q-M, Example 3Q-M, Example 4Q-M, Example 5Q-M, Comparative Example 1Q-M, Comparative Example 2Q-M according to body weight balance, with 10 mice in each group. The drugs were administered at a fixed time every day for 3 consecutive days. The mice were fasted but not watered 10 hours before the last administration; 1 hour after the last administration, the xylene-induced ear swelling experiment of mice was performed.

[0214] 5.3 Observation indicators

[0215] Cut off the left and right auricles, use an 8 mm ear swelling puncher to take the left and right ear pieces, weigh the masses of the left and right ear pieces, and calculate the swelling degree (mg) and swelling rate (%).

[0216] Swelling degree (mg) = right ear piece mass - left ear piece mass

[0217] Swelling rate (%) = [(right ear mass - left ear mass) / left ear weight] × 100%

[0218] 5.4 Experimental Results

[0219] Xylene-induced ear swelling in mice

[0220] The degree of ear swelling of mice in each group is shown in Table 16.

[0221] Table 16

[0222] Group Left ear(mg) Right ear (mg) CON 18.4±0.31 18.2±0.42 MOD 18.6±0.50 32.8±1.11**** ASA 18.2±0.39 23.2±0.51****#### Example 1Q-L 17.7±0.50 22.4±1.25***# Example 1Q-M 17.7±0.30 22.1±0.69****### Example 1Q-H 17.5±0.61 21.2±1.01**### Example 2Q-M 17.2±0.26 23.0±0.08* Example 3Q-M 18.3±0.56 23.6±0.67* Example 4Q-M 18.2±0.73 22.1±0.45**## Example 5Q-M 17.8±0.21 22.4±0.49**# Comparative Example 1Q-M 19.0±0.02 25.3±0.78 Comparative Example 2Q-M 18.8±0.89 27.0±0.11

[0223] Note: Compared with the Control group, ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05;

[0224] Compared with the Model group, ####P<0.0001, ###P<0.001, ##P<0.01, #P<0.05

[0225] Compared with CON, the MOD right ear auricle was red and swollen after xylene was evenly applied on both sides, the skin was thickened, and the capillaries were significantly dilated, indicating that the model was successful. Compared with MOD, each drug-treated group had a significant inhibitory effect on the ear swelling caused by xylene, among which ASA had the best anti-inflammatory effect (P<0.0001), and QH and QM had significant anti-inflammatory effects (P<0.001), as shown in Table 16.

[0226] Experimental Example 6

[0227] Experiment on acetic acid-induced capillary permeability in mice

[0228] 6.1.1 Experimental animals

[0229] SPF female KM mice, 5 weeks old, weighing 18-22 g, 50 mice, provided by Zhuhai Baishitong Biotechnology Co., Ltd., laboratory animal production license number SYXK (Guangdong) 2022-0125. After 7 days of adaptive feeding, the experimental period began.

[0230] 6.1.2 Experimental reagents

[0231] The experimental reagents are shown in Table 17.

[0232] Table 17

[0233] Product Name factory batch number Xylene Tianjin Damao Chemical Reagent Factory - Evansland meilunbio -

[0234] 6.1.3 Experimental instruments

[0235] The experimental instruments are shown in Table 18.

[0236] Table 18

[0237] instrument factory Pipette BIOPAC 96-well plate Coring Incorporated Spectra i3X Multi-Mode Microplate Reader Beauty Valley, Shanghai

[0238] 6.2 Experimental methods

[0239] 6.2.1 Mouse capillary permeability experiment

[0240] After 3 days of adaptive feeding, SPF female KM mice (18-22g) were randomly divided into CON, MOD, ASA, Example 1Q-L, Example 1Q-M, Example 1Q-H, Example 2Q-M, Example 3Q-M, Example 4Q-M, Example 5Q-M, Comparative Example 1Q-M, Comparative Example 2Q-M according to body weight balance, with 10 mice in each group. The mice were fasted but not watered 10 hours before the last administration; 1 hour after the last administration, 0.6% acetic acid was injected intraperitoneally at 0.2mL / mouse. 25 minutes later, 2% Evans blue was injected into the tail vein at 0.2mL / mouse, and the mice were killed by cervical vertebrae dislocation 20 minutes later, the abdominal skin and muscles of the abdominal cavity were cut open, and the abdominal cavity was washed several times with 6mL of normal saline. The washing liquid was sucked out with a disposable pipette, combined, centrifuged at 3000r / min for 15 minutes, and the supernatant was taken to measure the OD value at 590nm colorimetry.

[0241] 6.3 Experimental Results

[0242] Analysis of the results of acetic acid-induced capillary permeability in mice

[0243] The OD values ​​of each group are shown in Table 19:

[0244] Table 19

[0245]

[0246]

[0247] Note: Compared with the Control group, ****P<0.0001, ***P<0.001, **P<0.01, *P<0.05;

[0248] Compared with the Model group, ####P<0.0001, ###P<0.001, ##P<0.01, #P<0.05

[0249] Compared with CON, the OD value of MOD was significantly increased (P<0.0001). Compared with MOD, the differences among the administration groups were significant, among which ASA had the best anti-inflammatory effect (P<0.0001), followed by QH (P<0.01), as shown in Table 19. From Comparative Examples 1-2, it can be seen that the composition must be within the range of the components and the weight proportions of the components set in the present invention to exert the best anti-inflammatory effect.

[0250] The above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit the same. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that the technical solutions described in the aforementioned embodiments may still be modified, or some of the technical features may be replaced by equivalents. However, these modifications or replacements do not deviate the essence of the corresponding technical solutions from the spirit and scope of the technical solutions of the embodiments of the present invention.

Claims

1. A Chinese medicine composition for preventing epidemic viruses, characterized in that: The Chinese medicine composition comprises the following components by weight: 10-15 parts of roasted ephedra, 10-20 parts of kudzu root, 10-15 parts of bupleurum, 10-20 parts of gypsum, 10-20 parts of tuckahoe, 10-20 parts of honeysuckle, 10-15 parts of forsythia, 10-15 parts of artemisia annua, 10-20 parts of cirsium japonicum, 10-15 parts of burdock fruit and 10-15 parts of platycodon.

2. The Chinese medicine composition according to claim 1, characterized in that: The composition comprises the following components by weight: 10 parts of roasted ephedra, 15 parts of kudzu root, 10 parts of bupleurum, 15 parts of gypsum, 15 parts of tuckahoe, 15 parts of honeysuckle, 10 parts of forsythia, 12 parts of artemisia annua, 15 parts of cirsium japonicum, 12 parts of burdock fruit and 10 parts of platycodon.

3. The Chinese medicine composition according to claim 1, characterized in that The weight ratio of honeysuckle, bupleurum and forsythia is 1.5-2:1.2-1.5:1.2-1.

5.

4. The method for preparing the Chinese medicine composition according to any one of claims 1 to 3, characterized in that: The method comprises the following steps: weighing roasted ephedra, kudzu root, bupleurum, gypsum, tuckahoe, honeysuckle, forsythia, artemisia annua, cirsium japonicum, burdock fruit and platycodon, soaking in water, decocting, filtering, concentrating, cooling and fixing the volume to obtain the traditional Chinese medicine composition.

5. The preparation method according to claim 4, characterized in that: The water-adding decoction adopts a condensation reflux device; the condensation reflux time is 0.5-1.5h; the number of condensation reflux is 1-3 times.

6. The preparation method according to claim 4, characterized in that: The mass ratio of the water added to the liquid is 1:5-25.

7. The preparation method according to claim 4, characterized in that: The soaking time is 0h-1h.

8. The preparation method according to claim 4, characterized in that: The concentration standard is to concentrate to less than 500 mL.

9. Use of the Chinese medicine composition according to any one of claims 1 to 3 in the preparation of anti-inflammatory, analgesic, heat-clearing and detoxifying products.

10. An anti-inflammatory, analgesic, heat-clearing and detoxifying product, characterized in that: The invention comprises the Chinese medicine composition described in any one of claims 1 to 3 or the Chinese medicine composition obtained by the preparation method described in any one of claims 4 to 8, wherein the dosage form of the product is granules, tablets, capsules or oral liquid.

Images